Spots Global Cancer Trial Database for hepatoma
Every month we try and update this database with for hepatoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma | NCT00861783 | Hepatoma Advanced Solid ... | irinotecan and ... oxaliplatin and... | 18 Years - | Traws Pharma, Inc. | |
| CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma | NCT05257590 | Hepatocellular ... Advanced Cancer | Nivolumab Injec... CVM-1118 | 18 Years - | TaiRx, Inc. | |
| Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma | NCT02191878 | Hepatocellular ... Hepatoma Liver Cancer, A... Liver Cell Carc... | TKM-080301 | 18 Years - | Arbutus Biopharma Corporation | |
| Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery | NCT02174575 | Hepatocellular ... Hepatoma Cholangiocarcin... Gallbladder Neo... | Sevoflurane Desflurane | 20 Years - | Tokyo Medical and Dental University | |
| Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | NCT03638206 | B-cell Acute Ly... Lymphoma Myeloid Leukemi... Multiple Myelom... Hepatoma Gastric Cancer Pancreatic Canc... Mesothelioma Colorectal Canc... Esophagus Cance... Lung Cancer Glioma Melanoma Synovial Sarcom... Ovarian Cancer Renal Carcinoma | CAR-T cell immu... | 4 Years - 70 Years | Shenzhen BinDeBio Ltd. | |
| Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma | NCT00861783 | Hepatoma Advanced Solid ... | irinotecan and ... oxaliplatin and... | 18 Years - | Traws Pharma, Inc. | |
| A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection | NCT01402908 | Cancer Liver Cancer Hepatocellular ... | PI-88 Placebo | 18 Years - | Cellxpert Biotechnology Corp. | |
| TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma | NCT01721941 | Hepatocellular ... | Phase I Dose le... Phase I dose le... Phase I Dose le... Phase I Dose le... | 18 Years - | Scripps Clinic Cancer Center | |
| Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads | NCT00054951 | Hepatocellular ... | MTC-DOX for Inj... | 18 Years - 80 Years | FeRx | |
| Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma | NCT04553458 | Hepatocellular ... | Radiofrequency ... Trance-arterial... Liver resection Combined radiof... Percutaneous et... Systemic chemot... Sorafenib Viscum Symptomatic tre... | 18 Years - | Sohag University | |
| A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere® | NCT00877136 | Liver Tumors Hepatocellular ... Hepatoma Neoplasms | TheraSphere® | 18 Years - | St. Joseph Hospital of Orange | |
| Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC) | NCT04601428 | Hepatocellular ... | IA therapy of H... | 18 Years - | Koo Foundation Sun Yat-Sen Cancer Center | |
| Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma | NCT00844883 | Hepatocellular ... Hepatoma | sorafenib LC Bead-TACE | 18 Years - | Yale University | |
| IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread | NCT01099631 | Cancer of the L... Liver Cancer Hepatoma Liver Neoplasms Biliary Cancer | Salmonella typh... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma | NCT02704130 | Hepatocellular ... Hepatoma Liver Cancer, A... Liver Cell Carc... Liver Cell Carc... | Transarterial e... Microwave Ablat... | 18 Years - 75 Years | Wake Forest University Health Sciences | |
| SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma | NCT00503867 | Carcinoma, Hepa... Hepatoma | SIR-Spheres mic... | 18 Years - | Sirtex Medical | |
| A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma | NCT02460991 | Hepatocellular ... Hepatoma Liver Cell Carc... | DEB-TACE Sorafenib | 18 Years - | Boston Scientific Corporation | |
| Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma | NCT00669136 | Hepatocellular ... Hepatoma Liver Cancer, A... Liver Cell Carc... Liver Cell Carc... Cancer of Liver Cancer of the L... Cancer, Hepatoc... Hepatic Cancer Hepatic Neoplas... Hepatocellular ... Liver Cancer Neoplasms, Hepa... Neoplasms, Live... | AFP + GM-CSF Pl... | 18 Years - 80 Years | University of Pittsburgh | |
| A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere® | NCT00877136 | Liver Tumors Hepatocellular ... Hepatoma Neoplasms | TheraSphere® | 18 Years - | St. Joseph Hospital of Orange | |
| Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced Hepatocellular Carcinoma | NCT00910572 | Hepatocellular ... Liver Cancer | Yttrium-90 micr... | 18 Years - 80 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced Hepatocellular Carcinoma | NCT00910572 | Hepatocellular ... Liver Cancer | Yttrium-90 micr... | 18 Years - 80 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma | NCT00669136 | Hepatocellular ... Hepatoma Liver Cancer, A... Liver Cell Carc... Liver Cell Carc... Cancer of Liver Cancer of the L... Cancer, Hepatoc... Hepatic Cancer Hepatic Neoplas... Hepatocellular ... Liver Cancer Neoplasms, Hepa... Neoplasms, Live... | AFP + GM-CSF Pl... | 18 Years - 80 Years | University of Pittsburgh | |
| A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma | NCT00790218 | Hepatocellular ... | CF102 | 18 Years - 80 Years | Can-Fite BioPharma | |
| Study of Hepatoma Treated by Perfusing Cinobufacin Through Hepatic Artery Combining Embolotherapy | NCT01236690 | Hepatoma Cinobufacin Inj... | Cinobufacin inj... | 18 Years - 70 Years | Changhai Hospital | |
| Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced Hepatocellular Carcinoma | NCT00910572 | Hepatocellular ... Liver Cancer | Yttrium-90 micr... | 18 Years - 80 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC | NCT03380130 | Hepatocellular ... | Nivolumab SIR-Spheres | 18 Years - | Clinica Universidad de Navarra, Universidad de Navarra | |
| Liver and Biliary Tumor Tissue Registry | NCT02917759 | Hepatocellular ... Cholangiocarcin... | 18 Years - | Mayo Clinic | ||
| Durvalumab and Tremelimumab in Resectable HCC | NCT05440864 | Hepatocellular ... | Tremelimumab | 18 Years - | University Health Network, Toronto | |
| Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an Option | NCT00740753 | Liver Cancer Hepatoma | Yttrium 90 (The... | 18 Years - | OHSU Knight Cancer Institute | |
| PI-88 in Hepatocellular Carcinoma After Hepatectomy | NCT00247728 | Carcinoma, Hepa... | PI-88 | 18 Years - 75 Years | Cellxpert Biotechnology Corp. | |
| Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma | NCT00539643 | Hepatocellular ... Liver Cancer Hepatoma | Bead Block micr... Bead + Dox Arm | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma | NCT00503867 | Carcinoma, Hepa... Hepatoma | SIR-Spheres mic... | 18 Years - | Sirtex Medical | |
| A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors | NCT04567615 | Hepatocellular ... Hepatoma Liver Cancer, A... Liver Cell Carc... Liver Cell Carc... | Nivolumab Relatlimab | 18 Years - | Bristol-Myers Squibb | |
| Drug-loadable（T-ACE Beads）for Hepatoma Embolization Therapy | NCT03299036 | Cancer of Liver | Taiwan ACE Bead... | 20 Years - | National Cheng-Kung University Hospital | |
| Study of Hepatoma Treated by Perfusing Cinobufacin Through Hepatic Artery Combining Embolotherapy | NCT01236690 | Hepatoma Cinobufacin Inj... | Cinobufacin inj... | 18 Years - 70 Years | Changhai Hospital | |
| Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma | NCT01008917 | Hepatocellular ... | sorafenib with ... | 18 Years - | University of California, San Francisco | |
| TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma | NCT01721941 | Hepatocellular ... | Phase I Dose le... Phase I dose le... Phase I Dose le... Phase I Dose le... | 18 Years - | Scripps Clinic Cancer Center | |
| Liver and Biliary Tumor Tissue Registry | NCT02917759 | Hepatocellular ... Cholangiocarcin... | 18 Years - | Mayo Clinic | ||
| Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7 | NCT04777851 | Carcinoma, Hepa... | Regorafenib in ... Loco-regional t... | 18 Years - | Translational Research in Oncology | |
| Advanced Image Guidance Utilized in Liver Surgery | NCT01666145 | Carcinoma, Hepa... | Advanced Image ... | 18 Years - | Wake Forest University Health Sciences | |
| Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma | NCT00539643 | Hepatocellular ... Liver Cancer Hepatoma | Bead Block micr... Bead + Dox Arm | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC) | NCT00683631 | Hepatocellular ... | TheraSphere HUD | 18 Years - | University of Louisville | |
| Drug-loadable（T-ACE Beads）for Hepatoma Embolization Therapy | NCT03299036 | Cancer of Liver | Taiwan ACE Bead... | 20 Years - | National Cheng-Kung University Hospital | |
| Extracellular RNA Markers of Liver Disease and Cancer | NCT02908048 | Hepatocellular ... Biliary Tract C... Cirrhosis Liver Diseases | Blood samples | 18 Years - | Mayo Clinic | |
| Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma | NCT04553458 | Hepatocellular ... | Radiofrequency ... Trance-arterial... Liver resection Combined radiof... Percutaneous et... Systemic chemot... Sorafenib Viscum Symptomatic tre... | 18 Years - | Sohag University | |
| Durvalumab and Tremelimumab in Resectable HCC | NCT05440864 | Hepatocellular ... | Tremelimumab | 18 Years - | University Health Network, Toronto | |
| Assessment of Novel MRI Quantification Free Breathing Technique in Evaluation of Liver Lesions | NCT02095678 | Hepatocellular ... | liver biopsy free-breathing ... | 18 Years - 100 Years | Case Comprehensive Cancer Center | |
| Opioid Sparing Effect of Thoracic Epidural Analgesia for Open Upper Abdominal Surgery | NCT04920019 | Hepatoma Pancreas Cancer | Thoracic contin... | 18 Years - 80 Years | Mahidol University | |
| Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma | NCT01618253 | Hepatocellular ... Hepatocellular ... Hepatoma Liver Cancer | Sorafenib Conventional fr... | 18 Years - 80 Years | Medical College of Wisconsin | |
| Sorafenib and TRC105 in Hepatocellular Cancer | NCT01306058 | Hepatoma Liver Neoplasms Adenoma, Liver ... Carcinoma, Hepa... Liver Neoplasms... | TRC 105 Sorafenib | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery | NCT02174575 | Hepatocellular ... Hepatoma Cholangiocarcin... Gallbladder Neo... | Sevoflurane Desflurane | 20 Years - | Tokyo Medical and Dental University | |
| Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced Hepatocellular Carcinoma | NCT00910572 | Hepatocellular ... Liver Cancer | Yttrium-90 micr... | 18 Years - 80 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
